These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28659410)

  • 21. Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: A mathematical and computational examination.
    Garcia V; Bonhoeffer S; Fu F
    J Theor Biol; 2020 May; 492():110185. PubMed ID: 32035826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of a cancer dormancy model and control of immuno-therapy.
    Sheller B; D'Alessandro D
    Math Biosci Eng; 2015 Oct; 12(5):1037-53. PubMed ID: 26280178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized cancer immunotherapy using Systems Medicine approaches.
    Gupta SK; Jaitly T; Schmitz U; Schuler G; Wolkenhauer O; Vera J
    Brief Bioinform; 2016 May; 17(3):453-67. PubMed ID: 26174229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
    Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smart CARs engineered for cancer immunotherapy.
    Priceman SJ; Forman SJ; Brown CE
    Curr Opin Oncol; 2015 Nov; 27(6):466-74. PubMed ID: 26352543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
    Emens LA; Ascierto PA; Darcy PK; Demaria S; Eggermont AMM; Redmond WL; Seliger B; Marincola FM
    Eur J Cancer; 2017 Aug; 81():116-129. PubMed ID: 28623775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy.
    Wilkie KP
    Adv Exp Med Biol; 2013; 734():201-34. PubMed ID: 23143981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of tumour-immune evasion with chemo-immuno therapeutic treatment with quadratic optimal control.
    Ravindran NS; Sheriff MM; Krishnapriya P
    J Biol Dyn; 2017 Dec; 11(1):480-503. PubMed ID: 28976297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local tumour hyperthermia as immunotherapy for metastatic cancer.
    Toraya-Brown S; Fiering S
    Int J Hyperthermia; 2014 Dec; 30(8):531-9. PubMed ID: 25430985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
    Gibney GT; Weiner LM; Atkins MB
    Lancet Oncol; 2016 Dec; 17(12):e542-e551. PubMed ID: 27924752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico modelling of treatment-induced tumour cell kill: developments and advances.
    Marcu LG; Harriss-Phillips WM
    Comput Math Methods Med; 2012; 2012():960256. PubMed ID: 22852024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [At the crossroads of cancer].
    Chouaib S
    Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mathematical model of tumour growth with Beddington-DeAngelis functional response: a case of cancer without disease.
    Wei HC
    J Biol Dyn; 2018 Dec; 12(1):194-210. PubMed ID: 29322865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy.
    Cai Y; Zhang J; Li Z
    Biomed Eng Online; 2016 Dec; 15(Suppl 2):155. PubMed ID: 28155728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome.
    Guhathakurta D; Sheikh NA; Meagher TC; Letarte S; Trager JB
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):387-401. PubMed ID: 23927667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SysBioMed report: advancing systems biology for medical applications.
    Wolkenhauer O; Fell D; De Meyts P; Blüthgen N; Herzel H; Le Novère N; Höfer T; Schürrle K; van Leeuwen I
    IET Syst Biol; 2009 May; 3(3):131-6. PubMed ID: 19449974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.